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Abstract
Objective:
The aim of this study was to prospectively assess the efficacy and safety of sublingual fentanyl (SLF) in doses
proportional to opioid doses used for background analgesia for the treatment of BTP of cancer patients.
Methods:
A sample of patients admitted to an acute palliative care unit, presenting breakthrough pain (BTP) episodes
and receiving stable doses of opioids for background pain was selected to assess the efficacy and safety of
SLF used in doses proportional to the basal opioid regimen used for the management of BTP. For each
patient, data from four consecutive episodes were collected. For each episode, nurses collected changes in
pain intensity and adverse effects when pain got severe (T0), and 5, 10, and 15 minutes after SLF was given
(T15).
Results:
Seventy patients were recruited for the study. The mean age was 61.7 (11.5). Forty-one patients were
males. A total of 173 episodes of BTP were recorded (mean 2.5 episodes/patient). In 19 events,
documentation regarding changes in pain intensity was incomplete. Of the 154 evaluable episodes, 143
were successfully treated (92%). Mean doses of SLF were 637 mg (SD 786), and 51 patients (72.8%)
received SLF doses 800mg. When compared to younger adult patients, older patients received
significantly lower doses of FBT (p50.0005), similarly to their lower basal opioid regimen. Pain intensity
significantly decreased at T5, 10 and T15 (p50.0005). The number of patients with a pain reduction of
more than 33% at T5, T10, and T15 were 11, 79, and 137, respectively, and the number of patients with
a reduction in pain intensity of more than 50% were 1, 21, 114 at the same intervals, respectively. No
differences in changes in pain intensity for gender (p50.9) or age (p50.85) were observed. No significant
changes in the number of patients reporting adverse effects of mild–moderate intensity were reported after
SLF administration in comparison with baseline, and no adverse effects severe enough in intensity to require
medical intervention were observed. Limitations of this study are represented by the uncontrolled design.
Conclusion:
This study suggests that SLF given in doses proportional to the basal opioid regimen for the management
of BTP is safe and effective in clinical practice.
Introduction
According to a prevalent definition, breakthrough pain (BTP) is a transitory
exacerbation of pain, severe in intensity and with a rapid onset, superimposed on
an otherwise stable pain pattern in patients treated with opioids1–3. The pres-
ence of BTP has been considered as a negative prognostic factor, and influences
the quality of life of these patients4. The availability of supplemental doses of
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opioids in addition to continuous analgesic medication is
the main treatment suggested for management of these
pain flares, either during dose titration or when basal
pain is under control. Anecdotal experience with oral opi-
oids suggests that an effective dose of BTP medication
must be a percentage of a patient’s total daily opioid
dose5. However, the onset time of oral opioids is expected
to be 30–45 minutes. As pain relief is usually required
urgently in most cases, in the last decade new routes of
administration have been designed to provide fast pain
relief. The use of these fentanyl delivery systems, com-
monly named rapid onset opioids (ROOs) has been
shown to provide the best effective treatment in compari-
son with placebo or oral morphine6.
Most trials performed with ROOs suggest titrating doses
to achieve an effective dose, as there is no relationship
between effective fentanyl dose and a fixed schedule
opioid regimen7–9. However, the evidence is only indirect,
because it was never the primary outcome and was derived
from the study design rather than on convincing compara-
tive studies of dosing strategies. In these regulatory studies
designed to find a dose to be compared with placebo or
active drugs, a substantial proportion of patients failed dose
titration with any product used to delivery transmucosal
fentanyl. Moreover an unclear distinction between basal
pain of mild–moderate intensity and BTP of moderate–
severe intensity make the interpretation of data provided
by these studies difficult10. In clinical practice, low doses of
ROOs, started in an attempt to titrate the doses individu-
ally, are unlikely to produce any effect in patients receiving
high doses of opioids for their background pain, and may
result in unnecessary suffering. Dose titration may make
the practical use of ROOs difficult in daily activity,
particularly at home or in outpatients. Patients may be
reluctant to try the dose and avoid using these drugs11,12,
preferring, in the end, traditional oral dosing of
morphine13.
A predictable dose could favour an easy prescription,
resulting in better patient compliance. The principal prob-
lem concerns the risk of toxicity. However, the use of pro-
portional doses has been shown to be safe and effective in
a large number of patients, in open-label and controlled
studies14–18. In the only existing study comparing titration
strategy with the proportional approach, the latter was
found to be more effective while the adverse effects were
similar19.
Sublingual fentanyl (SLF) is a second generation ROO,
formulated as a rapidly disintegrating tablet system con-
taining a mixture of carrier particles coated with active
drug particles and containing a mucoadhesive agent. The
bioavailability of SLF is estimated to be about 70%20, with
an interindividual variability lower than that reported
with oral transmucosal fentanyl21. Controlled studies
have demonstrated the efficacy and safety of SLF for the
management of BTP22,23. In the former study, higher doses
were more effective, possibly in patients receiving higher
doses of opioids used for background analgesia, and with
similar profiles of adverse effects in comparison with lower
doses, suggesting the use of proportional doses. The aim of
this study was to prospectively assess the efficacy and safety
of SLF in doses proportional to opioid doses used for back-
ground analgesia for the treatment of BTP of cancer
patients admitted in an acute pain relief and supportive
care unit. Age was also considered as a possible factor
influencing the outcome. The secondary aim was to evalu-
ate a possible early onset of SLF.
Methods
A sample of patients consecutively admitted to an acute
palliative care unit in a period of 12 months, from May
2012 to April 2013, was surveyed. From this sample,
patients who were receiving opioids in doses of oral mor-
phine equivalents equal to or more than 60mg daily, and
having well controlled background pain and presenting3
BTP episodes/day, were selected. Patients who were asked
to participate were prescribed SLF in doses proportional to
opioids used for background analgesia. According to con-
solidated local policy and previous published experi-
ence14–19 to calculate the dose, for example, the minimal
existing dose 100 mg was given to patients receiving 60mg
of oral morphine equivalents, 200 mg was given to patients
receiving 120mg of oral morphine equivalents, and so on.
Informed consent and institutional approval were
obtained.
Patients were treated according to a routine protocol.
After establishing around the clock opioid medication,
according to opioid titration process, achieving a stable
analgesia, with mean pain intensity of4/10 (on a numer-
ical scale of 0–10), for two consecutive days, patients were
instructed to call for administering SLF at the doses calcu-
lated when a superimposed episode of BTP occurred. For
each episode of BTP, trained nurses recorded patients’
assessed pain intensity (numerical scale 0–10), and adverse
effects measured on a scale from 0 to 3 (absent, mild, mod-
erate, and severe), as well as adverse effects severe enough
in intensity to require medical intervention. Recording
was performed just before giving the SLF dose (T0), and
5, 10 and 15 minutes after (T5, T10, and T15, respect-
ively). The administration of SLF was considered unsuc-
cessful whenever further BTP medication was required in
the subsequent 2 hours. To evaluate the efficacy of SFL,
the number of episodes which were successfully treated
using SLF in doses proportional to the basal opioid regi-
men, within 15 minutes, was assessed. Safety was assessed
by measuring the changes in adverse effects intensity and
the occurrence of adverse effects severe enough in inten-
sity to require a medical intervention. Changes in pain
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intensity were also assessed to evaluate possible earlier
analgesic effects of SLF (5 and 10 minutes).
Statistical analysis
Frequency analysis was performed using Pearson’s chi-
squared test and Fisher’s exact test. One-way analysis of
variance (ANOVA) and the Kruskal Wallis statistic test
were used to compare the different parametric or non-
parametric variables. For analysis, patients were divided
according to age: 65 years and 465 years. Data was
analysed with SPSS Software 14.0 version (SPSS Inc.,
Chicago, IL, USA). All p-values were two sided, and
p-values less than 0.05 were considered statistically signifi-
cant. On the basis of previous similar studies14–19, a sample
of 150 episodes was considered sufficient to determine the
efficacy and safety of this approach.
Results
Seventy patients were administered SLF. The primary
diagnosis was in a rank order: lung 24, uro-gynaecological
15, pancreas 10, colon 5, breast 5, others 11.
Characteristics of patients are reported in Table 1. The
mean age was 61.7 (11.5), and 27 (38.6%) patients
were over 65 years. Forty-one patients were males.
A total of 173 episodes of BTP were recorded (mean 2.5
episodes/patient). In 19 events, documentation regarding
changes in pain intensity was incomplete in the record
sheet (12, 4, 2, 1 events were incomplete at T0, T5,
T10, and T15, respectively). Of the 154 evaluable epi-
sodes, 143 were successfully treated (92%), without any
further request. Mean doses of SLF are reported in
Table 1. Fifty-one patients (72.8%) received SLF doses
800 mg. When compared to younger adult patients,
older patients received significantly lower doses of fentanyl
buccal tablet (FBT) (p50.0005).
Pain intensity significantly decreased at T5, T10 and
T15 (p¼50.0005). The percentage of patients with a pain
reduction of more than 33% at T5, T10, and T15, and the
percentage of patients with a reduction in pain intensity
of more than 50% at T5, T10, and T15, are reported
in Table 2. No differences in changes in pain intensity
for gender (p50.9) or age (p50.85) were observed.
The main adverse effects, drowsiness and nausea, gen-
erally of low intensity, were already present, due to basal
opioid treatment or disease. No significant changes in
the number of patients reporting adverse effects of mild–
moderate intensity were reported after SLF administration
in comparison with baseline (numbers of patients and
p values are reported in Table 2). Finally, no adverse effects
severe enough in intensity to require medical intervention
were observed.
Discussion
The finding sof this study suggest that SLF, used in pro-
portional doses to opioid basal regimen for the manage-
ment of BTP, is as effective as safe, also considering that
most patients received relatively high doses of SLF. This
data confirms previous observations reported with other
ROOs and intravenous morphine6, even in patients
receiving high doses of opioids for background analgesia
without adding risks of occurrence of adverse effects17,
or in patients followed at home, which is the least
protected setting24.
Table 1. Characteristics of patients, number of episodes collected, mean doses of SLF (mg), oral morphine equivalents (mg/day), and
changes in pain intensity at the different time intervals (see text). Standard deviation (SD) in brackets.
N patients All Age 65 yrs Age465 yrs p
M/F 41/29 26/17 15/12 0.685
Age 61.7 (11.5) 54.6 (8.1) 73.1 (5.2) /
Evaluable episodes 173 111 62 /
Mean dose of SLF (SD) 637 (786) 765 (954) 433 (311) 50.0005
Oral morphine equivalents for background pain (SD) 362 (320) 420 (480) 245 (210) 50.0005
T0 Pain intensity 7.0 (1.1) 7.1 (1.1) 6.7 (0.9) 0.016
T5 Pain intensity 6.0 (1.1) 6.1 (1.2) 5.9 (0.9) 0.152
T10 Pain intensity 4.9 (1.4) 4.9 (1.4) 4.8 (1.4) 0.535
T15 Pain intensity 3.6 (1.6) 3.6(1.5) 3.5 (1.7) 0.218
Table 2. Number of BTP episodes with a decrease in PI433% and 50%,
and changes of adverse effect intensity after administration of SLF.
N patients All Age 65 yrs Age465 yrs p
Number of BTP episodes with a decrease in PI433%
At T5 11 8 3 0.748
At T10 79 48 31 0.428
At T30 137 85 52 0.329
Number of BTP episodes with a decrease in PI450%
At T5 1 1 0 1
At T10 21 15 6 0.628
At T15 114 69 45 0.184
Number of patients with adverse effects at baseline (T0) and after SLF
(T5, T10, T15)
At T0 71 43 28 0.424
At T5 74 46 28 0.748
At T10 75 45 30 0.340
At T15 76 47 29 0.632
BTO¼ breakthrough pain, PI¼ pain intensity, SLF¼ sublingual fentanyl
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These findings contradict general recommendations,
which suggested that the dose of ROOs to be given for
an episode for BTcP should be determined by individual
titration7. There are several considerations which biased
this statement, inherited in the literature, and largely
examined in previous analyses11,12. During the titration
phases reported in the literature, 10–30% of episodes trea-
ted may fail during dose titration, particularly in patients
receiving high doses of opioids. As a consequence all these
studies should be considered as enrichment trials, where
the bad patients were excluded, and the responsive ones
were compared with active substances (oral opioids) or
placebo. The need of dose titration has never been specif-
ically examined, and information gathered is just conse-
quential to the study design aimed to demonstrate the
superiority of ROOs over placebo or oral opioids, or to
evaluate the safety and efficacy of ascending doses of
ROOs. In fact, the titration period is an uncontrolled
open phase12. The need for titration is only based on the
observation that there is no correlation between the basal
opioid regimen and the effective dose found after dose
titration. The reasons for the lack of relationship between
doses for BTP and basal opioid regimen have not been
clearly explained, considering that the presence of toler-
ance should suggest a dose proportional to that used for
background analgesia, according to consolidated experi-
ence with the use of oral opioids for BTP, although even
this procedure is devoid of specific evidence.
From the practical point of view, dose titration
may make the practical use of any ROO difficult in daily
activity, particularly at home or in outpatient clinics.
Considering the different presentation of each single
episode, potentially titration should be performed for
each event. Using different pieces of ROOs for treating
each episode may be time consuming and may exceed
the spontaneous duration for BTP which can spontan-
eously subside, as evidenced by the numerous successful
placebo-treated patients reported in the literature11,12.
As a consequence, patients should be prescribed more
packages with different doses, unless using more pieces of
lower doses. Finally, most patients may be reluctant to try
the dose and avoid using these drugs, preferring, in the end,
traditional oral dosing of morphine13.
It could be argued that a proportional dose without
titration could expose patients to the risks of adverse
effects. In practice, although dose titration may appear
safer, at the end it requires doses similar to those resulting
from proportional doses and may result in more failures,
prolonging patients’ suffering and reducing their compli-
ance. A simulation of a calculation of doses of opioids used
for background analgesia and those achieved after individ-
ual titration showed mean values of proportional doses
very close to those found after titration10. In a ‘real
world’ study reproducing a clinical scenario of patients
receiving opioids for BTP, while the dose of oral opioids
used as rescue medication was 18% of the around the clock
opioid dose, for oral transmucosal fentanyl titrated to
determine the effective dose, the rescue dose was about
35% of the around the clock dose25, suggesting that the
titration process may provide even higher doses than those
expected by using proportional doses to the basal regimen.
Several observational studies on large sample of patients
and controlled studies have shown that the use of propor-
tional doses of ROOs is both effective and safe14–19.
Recently, the titration method was compared with propor-
tional doses of fentanyl buccal tablet (FBT), which has
similar availability to that of SLF. In patients receiving
proportional doses, efficacy was better in patients receiving
doses of oral morphine equivalents of 4120mg/day, in
comparison with the titration group, and the need of
rescue doses was significantly more often reported in the
titration group for the first episode of BTP. Importantly,
this outcome was not associated with differences in adverse
effects intensity between the two groups19. In other words,
the use of doses proportional to the opioid basal regimen,
easy calculable, could be more effective, without exposing
patients to more adverse effects, as suggested by several
practical experiences with intravenous morphine and
ROOs, even at high doses and in elderly patients11,12.
This is explained by the protective role of the level of
tolerance, which is related with the doses of opioids used
for the background pain. It has been shown that there is
tolerance to adverse effects in patients chronically exposed
to opioids, despite serum fentanyl levels as high as 6–8 ng/
mL26. Therefore, while titration is a mandatory process to
optimize background analgesia in individuals, in a tolerant
patient this process may loose priority, as patients have a
known level of tolerance to opioids and a proportional
dose may be predictably effective, without risks of adverse
effects. The number of patients with possibly opioid-
induced adverse effects did not change significantly after
SLF administration. It is of interest that no difference was
found in the intensity of adverse effects in comparison with
episodes treated in patients receiving lower doses. Finally,
no adverse effects severe enough in intensity to require
medical intervention were observed. SLF was used even
in high doses (800 mg) in about 50% of patients and epi-
sodes, resulting safe other than being effective. Older
patients received lower doses. This finding was expected
and reflects the lower opioid doses used for background
analgesia, as commonly reported in the literature27,28.
These data suggest that SLF given in doses proportional
to opioid basal regimen does not add to risk of overdosage,
even in older patients or when used at high doses.
In this study it has also been shown that a decrease of
33% and 50% in pain intensity may be achievable in
51% and 13% of patients, respectively, within 10 minutes,
while the figures were lower when assessing pain intensity
at T5 (21% and 1%, respectively), suggesting an onset of
clinical effect of 10 minutes in about 50% of patients,
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depending on which cut-off of pain intensity is used. This
finding confirms pharmacokinetics studies in which a
detectable plasma concentration of fentanyl occurred in
8–11 minutes21. A reduction of approximately two points
or a reduction of approximately 30% of pain intensity has
been reported to be a cut-off for clinically important dif-
ference29. Recently, in a study assessing meaningful pain
intensity after BTP medication, the majority of patients
requested a level of pain of 3.5 for adequate analgesia,
which was half of the intensity of BTP30.
It is of interest that the availability of 300 mg strength
with SLF is an added value, when using proportional doses,
as there is a minimal need to round the doses (for example
in a patient receiving 180mg/day of oral morphine
equivalents).
In a previous study of SLF performed in patients receiv-
ing an opioid regimen equivalent to 30–1000mg/day of
oral morphine or 25–300mg/h of transdermal fentanyl,
400 mg of SLF was significantly more effective in reducing
pain intensity and requirement for rescue analgesia than
placebo, in comparison with 100 mg and 200 mg of SLF or
placebo. Unfortunately the dose of around the clock opioid
medication was not reported, and it was not possible to
assess the relationship between fentanyl doses and basal
opioid regimen. It is of interest that adverse effects were
mild–moderate and did not increase with increasing SLF
dose22. In other words, higher doses of SLF were more
effective, without adding to risk of adverse effects. In a
traditional protocol where SLF was titrated to the success-
ful dose, SLF was compared with placebo in patients
receiving oral morphine equivalents of 60–1000mg or
transdermal fentanyl in doses of 50–300mg/h. SLF pro-
vided significant improvements in pain intensity at 30
minutes and 60 minutes and from 10 minutes post-dose
relative to placebo23. No raw data on doses of opioids
were provided, so no analysis on possible correlations
between basal opioid regimen and successful SLF dose
was performed.
The principal limitation of this study is represented by
the open-label non-comparative nature of this study.
However, the aim was not to assess the efficacy in com-
parison with placebo, as this information already existed.
This pilot study reproduces a typical clinical scenario
where calculating the dose to be administered may provide
easy prescription for patients while assuring efficacy and
safety, as already observed with other fentanyl delivery
systems. On the other hand, as mentioned before, titration
phases in controlled studies were open.
Conclusion
SLF administered in doses proportional to basal opioid
regimen for background pain seems to be effective, provid-
ing optimal analgesia in the majority of treated episodes of
BTP, and devoid of important adverse effects, reproducing
previous observations reported with other ROOs.
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